Financial reports
10-K
2023 FY
Annual report
16 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
10-Q
2023 Q3
Quarterly report
20 Nov 23
NT 10-Q
Notice of late quarterly filing
14 Nov 23
10-Q
2023 Q2
Quarterly report
21 Aug 23
NT 10-Q
Notice of late quarterly filing
14 Aug 23
10-Q
2023 Q1
Quarterly report
22 May 23
NT 10-Q
Notice of late quarterly filing
15 May 23
10-K
2022 FY
Annual report
17 Apr 23
NT 10-K
Notice of late annual filing
30 Mar 23
Current reports
8-K
Entry into a Material Definitive Agreement
21 Mar 24
8-K
Entry into a Material Definitive Agreement
13 Feb 24
8-K
Entry into a Material Definitive Agreement
28 Dec 23
8-K
Entry into a Material Definitive Agreement
2 Jun 23
8-K
Entry into a Material Definitive Agreement
30 May 23
8-K
Departure of Directors or Certain Officers
25 May 23
8-K
Entry into a Material Definitive Agreement
27 Jan 23
8-K
Company to Sell, Distribute AXIM’s Readers and Three Proprietary Tests Designed for Diagnosis of Dry Eye Disease Globally Through New Agreement
19 Sep 22
8-K
Entry into a Material Definitive Agreement
29 Aug 22
8-K
AXIM Biotech Launches For Research Use Only Sales for its COVID-19 Neutralizing Antibody Test
9 Mar 22
Registration and prospectus
S-1
IPO registration
2 Jun 23
S-1/A
IPO registration (amended)
1 Aug 22
S-1
IPO registration
22 Jul 22
S-8
Registration of securities for employees
14 Jun 22
S-1/A
IPO registration (amended)
9 Jun 21
S-1
IPO registration
14 May 21
D
$5M in equity / debt / options / securities to be acquired, sold $500K, 1 investor
15 Jun 20
424B5
Prospectus supplement for primary offering
17 Dec 19
D
$600K in equity, sold $600K, 1 investor
21 May 18
424B5
Prospectus supplement for primary offering
18 Apr 18
Other
EFFECT
Notice of effectiveness
12 Jun 23
UPLOAD
Letter from SEC
7 Jun 23
CORRESP
Correspondence with SEC
7 Jun 23
EFFECT
Notice of effectiveness
5 Aug 22
CORRESP
Correspondence with SEC
2 Aug 22
UPLOAD
Letter from SEC
29 Jul 22
EFFECT
Notice of effectiveness
23 Jun 21
CORRESP
Correspondence with SEC
21 Jun 21
UPLOAD
Letter from SEC
19 May 21
UPLOAD
Letter from SEC
10 Jan 20
Ownership
4/A
JOHN WALTER HUEMOELLER II
19 Mar 24
4
Catalina Valencia
19 Mar 24
4
Blake Schroeder
19 Mar 24
4
Robert L Cunningham
19 Mar 24
4
Timothy Richard Scott
19 Mar 24
4
Peter O'Rourke
19 Mar 24
4
ROBERT MALASEK
19 Mar 24
4
JOHN WALTER HUEMOELLER II
19 Mar 24
3
Kurt Phinney
30 May 23
144
Notice of proposed sale of securities
7 Oct 22